US stock futures muted as rate cut bets wane ahead of Jackson Hole
SARASOTA, FL - Silo Pharma, Inc. (NASDAQ:SILO) announced Thursday the publication of preclinical research for its Alzheimer’s disease therapeutic, SPC-14, in the peer-reviewed journal Alzheimer’s Research & Therapy.
The study, titled "Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer’s disease," showed that the combined administration of (R,S)-ketamine with prucalopride improved cognitive decline by increasing memory retrieval in a fear conditioning model in mice.
SPC-14 is an intranasal therapeutic targeting glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer’s disease.
The research was conducted under a sponsored research agreement with Columbia University. In 2024, Silo entered into an exclusive global license agreement with Columbia University for further development, manufacturing, and commercialization of SPC-14.
Silo CEO Eric Weisblum, who co-authored the study, said the conclusion identifies SPC-14 as "a promising drug combination for therapeutic use in AD and contributes to advancements in discovering targeted therapies for the treatment of dementia in AD."
The company noted in its press release statement that the Alzheimer’s disease treatment market is projected to grow to $30.8 billion in 2033, at an 18.8% compound annual growth rate.
Silo Pharma describes itself as a developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.
In other recent news, Silo Pharma, Inc. announced positive safety results for its lead asset, SPC-15, an intranasal spray for post-traumatic stress disorder (PTSD). The FDA-requested 7-day large animal study confirmed that SPC-15 met safety standards, showing no toxicities and comparable systemic exposure to oral administration. Silo Pharma also completed dosing in the safety and toxicology study for SPC-15, with results expected within 60 days. Additionally, the company anticipates receiving data from further preclinical studies of SPC-15 within the next 30 to 90 days. Silo Pharma has been granted a Notice of Allowance for a patent related to SPC-15’s treatment technology, licensed from Columbia University. However, Silo Pharma received a Nasdaq notice for non-compliance with the minimum bid price requirement, although this does not immediately affect its listing or trading status. These developments indicate significant progress in Silo Pharma’s efforts to advance its PTSD treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.